Presence of Histatin-1 in Human Tears and Association with Aqueous Deficient Dry Eye Diagnosis: A Preliminary Study

Sushma Kalmodia1, Kyung-No Son1, Dingcai Cao1, Bao-Shiang Lee2, Bayasgalan Surenkhuu1, Dhara Shah1, Marwan Ali1, Arun Balasubramaniam1, Sandeep Jain1 & Vinay Kumar Aakalu1

The aims of this study were to determine if histatin-1 (H1) is present in normal human tears and whether tear levels of H1 varied between normal patients and those with aqueous deficient dry eye disease (ADDE). Patient samples were obtained from 11 normal patients and 11 severe ADDE patients. Relevant patient characteristics, including age, sex, and dry eye disease (DED) diagnostic parameters were collected. Multiple qualitative and quantitative methods were used to compare the concentration of H1 between patient groups. Mixed linear modeling was used to compare H1 levels between groups, and diagnostic performance was assessed using the receiver-operator-characteristic (ROC). ADDE patients had significantly lower H1 concentrations (85.9 ± 63.7 ng/ml) than the normal group (891.6 ± 196.5 ng/ml) (p < 0.001), while controlling for age and sex. ROC analysis indicated that H1 concentration is potentially a biomarker for ADDE (area under curve = 0.96). Reclassification of patients by DED parameters including, Ocular Surface Disease Index (OSDI) (≤13, >13) and Schirmer I (without anesthesia) (<10 mm, ≥10 mm) showed significant differences in H1 level (OSDI, p = 0.004) and Schirmer I (p = 0.010). In conclusion, this is the first preliminary report of the presence of H1 in human tears. H1 concentrations are lower in ADDE patients and H1 may have diagnostic potential in evaluation ADDE patients.

Dry eye disease (DED) is a common disorder that affects millions of patients1. Aqueous deficient DED (ADDE) is associated with lacrimal gland dysfunction and loss of the aqueous layer of tears2. Several causes for ADDE include, but are not limited to Sjögren’s syndrome (SS) and ocular Graft-versus-Host Disease (oGVHD). Loss of the aqueous layer of the tear film can be associated with ocular surface inflammation, tear hyperosmolarity and a reduction of a number of intrinsic tear components, like lacritin2,3. Characterizing which components of tears are lost in ADDE can inform our understanding of the pathophysiology of disease, advance development of diagnostic measures and potentially support rational therapeutic replacement of diminished components of the tear film.

Histatins are an important class of endogenous anti-microbial peptides (AMP)4. Other exemplary AMPs include LL-37 and β-defensins5. Histatin peptides are a histidine rich family of 12 peptides (histatin 1–12), arising from two genes HTN1 and HTN36. Histatins were first described as anti-fungal agents in the saliva but have since been found to have anti-viral, anti-bacterial, wound healing and even anti-inflammatory activities6,7. The most common variants of histatin peptides in saliva are H1, H3 and H5 and typically represent 20–30% of the total salivary histatin pool8,9. In whole saliva, the concentration of H1 without stimulation was 12.9 ± 3.7 µg/ml9. In saliva, H2, H4, H6–H12 are formed as proteolytic fragments of H1, H3 and H510. Saliva of patients with rheumatoid arthritis with oral sicca symptoms has been noted to have decreased levels of histatins, and there has been interest in testing the use of histatins as markers of disease11–13.

Recently, there has been some interest in the potential role of histatin peptides in the ocular surface and the lacrimal functional unit. Some authors have found presence of expression of histatins in components of the ocular surface and on Schirmer tear strip samples from patients14–16. It was also demonstrated that H1 is present in...
epithelia of accessory lacrimal glands of humans, corneal and conjunctival epithelia, and that H1 can promote migration of human corneal epithila17,18.

H1 is thought to be able to promote epithelial migration, adhesion, barrier integrity and reduces the effects of epithelial-mesenchymal transition promoting agents16. Such characteristics, if ascribed to an intrinsic component of the tear film would be important to a healthy ocular surface.

Given the increasing evidence that histatin peptides are present in the ocular surface and tear film unit and the evidence that H1 can promote epithelial wound healing17. We sought to test two questions:

- Do the tears of normal patients contain H1?
- Do the tears of patients with ADDE have diminished levels of histatins?

In this study, patients were considered to have ADDE if their Schirmer I at 5 minutes was less than 10 mm of wetting, vital dye staining of the cornea ≥ 0.5 on the National Eye Institute-Corneal Staining Score (NEI-CSS), and an OSDI score greater than 1320,21. We focused primarily on H1 as this is one of the most studied in saliva, has its epithelial trophic functions17,22.

### Table 1. Patient Characteristics and Histatin-1 Concentrations. Schirmer I = Testing, in 5 minutes. ADDE = aqueous-deficient dry eye. OSDI = Ocular Surface Disease Index. H1 = Histatin-1. se = standard error of the mean. %= Percentage.

| Risk Factors          | Normal (N = 11) Mean(se) or % | ADDE (N = 11) Mean(se) or % | p-value |
|-----------------------|-------------------------------|----------------------------|---------|
| Age (yrs)             | 44.6 ± 2.6                    | 53.5 ± 2.9                 | 0.032   |
| Male Sex              | 7(63.6%)                      | 6(54.6%)                   | 0.665   |
| Schirmer I (mm)       | 18.3 ± 2.5                    | 1.9 ± 0.8                  | <0.001  |
| OSDI                  | 1.9 ± 1.0                     | 33.8 ± 6.6                 | <0.001  |
| H1 (ng/ml)            | 891.6 ± 196.5                 | 85.9 ± 63.7                | <0.001  |

### Table 2. Risk Factors for ADDE. H1 = Histatin-1, the mean value between two eyes for each subject was used for odds ratio calculation. ADDE = Aqueous-deficient dry eye, OSDI and Schirmer I testing were not included in this analysis as they were used for disease status classification. The dependent variable is disease status (ADDE vs normal) and the independent variable is H1 with age as the control variable.

| Risk Factor          | Odds Ratio | Standard Error | p-value |
|----------------------|------------|----------------|---------|
| H1 (100 ng/ml increase) | 0.5       | 0.1            | 0.016   |
| Age (1 year increase) | 1.1       | 0.1            | 0.055   |
| Male sex             | 0.7       | 0.6            | 0.665   |

### Results

**Patient demographics and phenotypic characteristics.** Patient demographic, clinical data and statistical comparisons are shown in Tables 1 and 2. Compared to the normal group, the ADDE group had a higher age (53.5 yrs. ± 2.9 yrs. vs. 44.6 yrs. ± 2.6 yrs., p = 0.032 from t testing) and a comparable percentage of males (54.6% vs. 63.6%, p = 0.665 from Chi-square testing). Consistent with our clinical definition of ADDE, we found that the ADDE group had a significantly lower Schirmer I measurements [1.9 ± 0.8 mm vs. 18.3 ± 2.5 mm, p < 0.001 from t-testing] and higher OSDI score (33.8 ± 6.6 vs. 1.9 ± 1.0, p < 0.001 from t-testing) than the normal group (Table 1). With an average Schirmer I of 1.9 mm, our ADDE patient population consisted of severe disease phenotypes. Additional phenotypic data including: non-invasive tear break up time (NITBUT), NEI-CSS and Meiboscale scores23,24* are included in the Supplemental data section (Supplementary Table 1). Notably, NITBUT [(secs), p = 0.392] and NEI-CSS (0–15), p = 0.3045) were not significantly different between ADDE subgroups (SS and oGVHD) whereas, Meiboscale score (0–4) means were significantly different between SS and ADDE subgroups (SS, 0.4 ± 0.2 and oGVHD 1.1 ± 0.1, p = 0.0202) (Supplementary Table 1).

**Histatin-1 is present in normal human ocular surface washings.** Antibody specificity was confirmed using Immune Dot Blot (IDB) over a series of concentrations of synthetic H1 (Fig. 1). Notably synthetic H1 peptide was detected with greater dot density with increasing concentrations of peptide in solution. Scrambled peptide (SP) negative control was found to be undetectable (Fig. 1A). The presence of H1 in normal human tears was then assessed using IDB and Western Blot (WB) and found that H1 peptide is present in ocular surface washings (OSW). Positive control (Synthetic H1(Syn.H1)) and biological positive control (Saliva) showed similar results (Fig. 1B,C). A full-length WB image is shown in Supplementary Fig. S1. It should be noted that the IDB in Fig. 1A,B were performed at separate times and as such comparison of signal intensity between these experiments is not possible.
Multiple reaction monitoring (MRM) was then used to identify the presence or absence of H1 in OSW and to confirm or deny the WB and IDB results showing the presence of H1 in OSW, as this technique is not dependent upon antibody specificity. Targeted MRM detected the presence of H1 in solubilized Syn.H1, normal human tear/OSW and saliva (Fig. 2).
Histatin-1 levels are lower in ADDE patients than normal controls. OSW were tested using enzyme-linked immunosorbent assay (ELISA) from ADDE patients and normal controls (Fig. 3A). Random intercept mixed linear modeling with eyes nested in patients indicated that the diseased group had lower H1 concentrations than the normal group [85.9 ± 63.7 vs. 891.6 ± 196.5, β(se) = −805.7(206.5), p < 0.001]. Histatin level was significantly associated with age [β(se) = −36.1(11.5), p = 0.002], OSDI score [β(se) = −13.4(5.5), p = 0.016], Schirmer [β(se) = 20.9(10.00), p = 0.036]. H1 level did not depend on sex [β(se) = −255.2(272.8), p = 0.349]. To address the association with age, mixed linear modeling was performed to control for age and diagnosis of ADDE and found that H1 association with diagnosis was still significant [β(se) = −612.0(217.4), p = 0.005]. These results indicate that the difference in H1 concentrations between the diseased and normal subjects could not be accounted for by the differences in age.

In order to understand if estimates of total protein levels varied with or independently of H1 levels, (Fig. 3B) outliers (high and low H1 concentration of samples with available residual tears for testing in each group- normal, oGVHD, SS) were selected and evaluated by performing gel electrophoresis and Coomassie staining. The results of these tests showed, in general, that there was no strong relationship between total protein levels and H1 concentrations within each group and across all groups, indicating these may vary independently.

**Discussion**

The main findings of this study are that H1 is present in human tears and levels of H1 are significantly reduced in patients with ADDE. This study represents the first robust demonstration of H1 in human tears, building upon initial findings amongst multiple groups. Multiple qualitative and quantitative methods were used to confirm the presence of H1 in OSW. H1 was demonstrably present in human OSW using Immune Dot Blot (IDB), western immunoblotting, ELISA and MRM. Moreover, H1 expression level was found to vary significantly between normal and ADDE patients. This
demonstration of the presence of histatin in tears, and deficiency of H1 in ADDE, suggests that evaluation of H1 in the pathogenesis of disease and utility in diagnosis and therapy of ADDE merit further investigation. The potential importance of histatins in ocular surface biology is highlighted by their demonstrated importance as contributors to oral epithelial and salivary homeostasis. Additionally, the importance of histatin levels as potential diagnostics is shown by findings lower than normal salivary histatin levels in rheumatoid arthritis patients with oral sicca symptoms11,13.

Interestingly, previous non-targeted proteomics studies using traditional LC-MS methods have not demonstrated the presence of H1 in human tears59. It is possible H1 was not previously detected by LC-MS because of the limitations of traditionally used methodology and the superiority of MRM in directed testing for specific proteins in human bodily fluids26,27. Clinical phenotype of DED also seems to have a considerable effect on tear protein composition, with aqueous deficiency associated with greater alterations of protein expression patterns. Additionally, it should be noted that not many proteins appear to be selectively downregulated in dry eye disease, highlighting the importance of these altered proteins as potential markers or treatments of disease59. Moreover, variations in total protein level in tears did not correlate with levels of H1, suggesting that H1 concentrations vary independently of protein concentration in tears in general.

We found that H1 levels are lower in ADDE patients than normal patients. We also found that there was a negative association with age and H1 levels. After controlling for age, using statistical modeling, the association between H1 and ADDE diagnosis was still present, suggesting that age differences do not account for the association of low H1 levels and ADDE diagnosis. There was also a strong correlation of H1 concentration with gold standard diagnostic measures of DED, including OSDI and Schirmer I values. Post-hoc pairwise comparisons between subgroups demonstrated significantly different H1 concentrations between normal and oGVHD (p = 0.002), significant differences between normal and SS (p = 0.026) and no significant difference between SS and oGVHD (p = 0.576). It should be noted that this study was not designed to compare these subgroups and future, larger, studies will be needed for comparison of H1 levels in different subtypes of ADDE.

In the studied patient population, it was noted that H1 as a risk factor for having a diagnosis of ADDE, with a higher odds-ratio (OR) was stronger (OR = 0.5) than age (OR = 1.1) or sex (OR = 0.7) (Table 2). Specifically, it was noted that, for every increase in 100 ng/ml of H1, there was a 0.5 reduction in risk of ADDE. Also, of note is the strong association between H1 level and OSDI (Fig. 4B), which can sometimes vary independently of protein concentration in tears in general.

Figure 4. Statistical Analysis of H1 Concentration and Association with OSDI and Schirmer I. (A) ROC analysis of the sensitivity and specificity of H1 concentrations for detecting a diagnosis of ADDE in the tested population. Area under the ROC curve was 0.96 (95% CI = 0.87–1.00), consistent with the excellent ability of H1 concentration to be used to detect a diagnosis of ADDE in the studied population. (B) Testing the Ability of H1 Concentration to Detect Patients with High OSDI or Low Schirmer I values. Patients were reclassified to groups based on their OSDI scores and Schirmer I measurements. Based on OSDI classification, the H1 level was significantly lower in the high OSDI (“diseased”) than the normal group. Based on Schirmer I classification, H1 level was significantly lower in the low Schirmer I (“diseased”) than the normal group.

The presence of H1 in human tears and the decrease of H1 in patients with ADDE open several potential areas of inquiry. One, what is the physiologic importance of H1 in human tears and the tear functional unit as a whole? It has been reported that H1 is present in lacrimal epithelia, and that histatin peptides can enhance corneal epithelial migration30,39. Two, can H1 serve as a biomarker for ADDE? This would have to be investigated in future studies looking at different subtypes of ADDE with larger variation in severity. Additionally, changes in H1 levels in response to treatment of DED using anti-inflammatory or other treatment options would be of interest to investigate the use of H1 as a biomarker. Three, given the presence of H1 in tears and the reduction of these levels in ADDE, is there value to replacement of H1 in patients with ADDE? As noted prior, histatin peptides are critical components of the oral mucosal environment, playing important roles in wound healing, inflammation abrogation, epithelial trophism, and antibiosis41. Similarly, H1 can affect potential derangements seen in DED in corneal epithelia by enhancing migration30. Other authors have recently reported on the utility of histatin peptides in treating corneal epithelial wounds in rabbits32. Future studies assessing the effects of H1 replacement in models of ADDE or other relevant ocular surface diseases would be of considerable interest. Moreover, establishment
of the mechanisms of action of histatin peptides on corneal epithelia and other ocular surface tissues should be investigated.

This study should be considered in the context of increasing evidence that endogenous anti-microbial and other endogenous proteins contribute significantly to the immune and environmental responses and homeostasis of the ocular surface. There are multiple examples of important endogenous peptides, that change in disease states. For instance, human beta-defensin2 is expressed in conjunctival epithelial cells and increases in DED patients. Another example is the observed reduction of lipocalin and lactritin expression in DED patient.43–46. These types of associations have pathophysiologic importance, as is seen in the changes in surface tension and viscosity of the tear film with alterations in lipocalin expression. Lactritin, like histatin, is also noted to have numerous salutary effects on ocular epithelia47,48. Given the importance of these peptides and their derangement in DED, it is possible that divergence from normal physiologic peptide levels could affect ocular surface epithelial function. Future studies demonstrating dysfunction in ocular surface epithelia associated with abnormal peptide levels would also support the utility of restoring normal peptide levels, as a potential therapeutic approach to disease.43–47.

There are several limitations to consider in evaluating this preliminary study, including limited sample size, inclusion of primarily severe ADDE patients and minor technical limitations. Although, this study had a relatively small sample size (n = 22) and imperfect age matching, it is closely comparable to several recent studies examining various protein levels in tears of patients (which ranged from 3 patients per group to 25 patients per group)43,44,46. To address lack of age matching statistical methods were used to control for this issue, but cannot completely substitute for a perfectly matched study. Ideally, normative levels in a large group of patients would be collected prospectively in an independent confirmatory study. Additionally, the bulk of our tested ADDE patients had severe disease. In order to better evaluate the relevance of H1 levels in DED as a whole, multiple severities and types of DED should be tested. In order to evaluate the utility of H1 levels as biomarkers of disease, it will also be necessary to test concentrations in response to treatment. Additionally, testing of the association other potential biomarkers including Matrix metallopeptidase 9 (MMP-9) and hyperosmolarity with histatin levels would be of interest to determine the value of H1 levels as markers of ADDE or DED in general. All of these issues require a larger, prospectively designed and powered study with better age matching of groups. Finally, testing of other types of histatin peptides in tears will be of interest to see if different histatins vary with disease status or other patient characteristics.42. Technical limitations of this study include qualitative measurements of total protein in tears using Coomassie blue staining, which is inferior to other methods such as the REVERT ™ Total Protein Stain (LI-COR Biosciences, Lincoln, NE) stain. Moreover use of Coomassie staining to give relative amounts of protein in tear samples has been used in other publications and indicated that the staining of gels for this purpose gave a mid-range discriminative power.49. Given the small amount of sample available to us and the use of OSW as a source, we are unable to give quantitative data for total protein levels. Nevertheless, H1 was found to be mostly low in all ADDE patients whereas total protein was varied.

In conclusion, this study demonstrates that H1 is present in normal human tears and vary differentially between normal patients and those with ADDE. The results of this study also showed that H1 is a potentially useful diagnosti, as H1 levels correlated well with gold standard diagnostic measures including OSDI and Schirmer I. Given the numerous biological functions of histatin peptides, including epithelial trophic, wound healing, anti-microbial and immunomodulatory actions, which are targets of ideal ocular surface disease treatments, and their reduction in ADDE, it would be reasonable to hypothesize that histatins may play a role in ADDE pathophysiology. Future studies focused on this hypothesis are planned.

**Methods**

**Subject participants and classification.** This research study was conducted under a University of Illinois at Chicago Institutional Review Board approved protocol, adhering to the tenets of the Declaration of Helsinki and the Health Insurance and Portability and Accountability Act. Symptomatic patients with DED and asymptomatic healthy control subjects were enrolled, and informed consent was obtained from all participants after the nature and possible consequences of the research were explained.

Participants were divided into the following two groups: (1) normal controls (n = 11, 22 eyes) (2) ADDE (n = 11, 22 eyes), with two subgroups: (a) SS group (n = 4, 8 eyes) and (b) oGVHD (n = 7, 14 eyes). This sample size will allow detection of a group mean difference of 1.26 standard deviation for a power of 0.8 and a significance level of 0.05.

Classification of patients was determined as follows: the control group included individuals with no ocular symptoms, a Schirmer I test without anesthesia result exceeding 10 mm at 5 minutes and an Ocular Surface Disease Index (OSDI) score below 13. Patients were considered to have ADDE if their Schirmer I at 5 minutes was less than 10 mm of wetting, vital dye staining of the cornea ≥1 on the NEI-CSS, and an OSDI > 13. All endogenous Schirmer I testing is a standard test used as an element in the diagnosis of ADDE.55,56. SS diagnosis was based on a preexisting diagnosis from a board certified rheumatologist with either presence of specific serum auto-antibodies or the presence of a disease consistent biopsy and concomitant ADDE as noted above. oGVHD diagnosis was based on previously reported consensus guideline criteria.41. Briefly, it includes 4 subjective and 4 objective criteria, corneal staining OSDI, Schirmer I, tear production measurements, and conjunctival injection. All patients in the oGVHD group that were included in the study had a diagnosis of “definite” oGVHD.

Examination and testing order during clinical visits was performed in the following order: OSDI scoring, Schirmer I, slit lamp biomicroscopic examination of the ocular surface (using a broad beam at medium intensity), ocular surface washings/tear collection, Vital dye staining and evaluation of the ocular surface with fluorescein.

**Schirmer I testing (without anesthesia) and Ocular Surface Disease Index (OSDI).** Schirmer I testing was undertaken to measure tear production using Whatman filter strips #41 (Haag-Streit, Essex, UK),
After 5 minutes, the Schirmer strip was removed and the length of wetting (mm) was measured. OSDI scores range from 0–100 with higher scores associated with more severe DED or disability. OSDI score was calculated using the following formula, \( \text{OSDI} = \frac{\sum (\text{scores of all the questions}) \times 25}{\text{total number of questions}} \).

**Corneal staining.** Corneal staining score as measured by Lissamine Green dye staining (5 μL of 1% solution applied to each eye) using National Eye Institute-Corneal Staining score (NEI-CSS), grading scale. The NEI scale relies on a chart that divides the cornea into five sections and assigns a value from 0 (absent) to 3 (severe) to each section, based on the density of punctate keratitis, for a maximum of 15 points.

**Non-invasive tear breakup time (NITBUT).** NITBUT is the time (in seconds) it takes for distortions to appear in the image of concentric Placido rings that are reflected on the patient’s cornea by a keragraft (Oculus, Inc., Arlington, WA). Two types of NITBUT are measured by the Keragraft 5 M: (i) NITBUT-first is the time at which the first distortion of Placido rings occurs; and (ii) average NITBUT-is the average time of first breakup incidents in different locations in a corneal diameter of 8 mm. We have provided information on the average NITBUT to compare the tear breakup time amongst ADDE subgroups (oGVHD and SS) (Supplementary Table 1).

**Meibomian gland analysis.** Meibomian Gland imaging was performed using LipiView II Ocular Surface Interferometer (TearScience, Morrisville, NC). Meibomian gland dropout was graded using a 0 to 4 scale based on the area of Meibomian gland loss (0, 0%; 1, <25%; 2, 25%–50%; 3, 51%–75%; and 4, >75%). The score was recorded as “Meiboscale” for each eye.

**Tear collection.** Ocular surface washings (OSW) were performed for tear collection, following published protocols. OSW were preferred, as opposed to direct capture of tears with microcapillary tube, as sufficient tear volume was not present to directly collect tears from patients with ADDE. In order to maintain comparability the same method of collection for tears was performed for normal patients. Briefly, ocular surface washings were obtained using a 50 μL drop of preservative-free artificial tears (Refresh Optive Sensitive; Allergan, Inc.) instilled in the eye by pipette, and OSW were performed then after a 2-minute period, tears from the lower lid margin and inferior fornix of all patients using a blunt glass microcapillary tube (5 μL Drummond Micropacs, Cat.#21-170E; Thermo Fisher Scientific, Waltham, MA) were collected. OSW tears were stored in a sterile Eppendorf tube (Thermo Fisher (Cat.#9501)) at –80 °C.

**Saliva collection.** Unstimulated whole saliva was collected from normal subjects without known oral diseases including severe periodontitis or dry mouth. Saliva was collected similarly to published protocols. Briefly, without any stimulation, saliva is allowed to accumulate in the mouth and expelled into a sterile culture dish. Approximately, 2 mL of whole saliva was collected and centrifuged at 14000 RPM at 8 °C for 10 minutes; the supernatant was then used for experimentation. Saliva was collected only for use as a positive biological control to determine the presence or absence of H1 in tears (Figs 1A and 2).

**Histatin-1 synthesis.** Histatin-1 peptide was synthesized according to previous published protocol as Trifluoroacetic acid (TFA) salts. The sequence of the peptide was, DS(PO3)HEKRHHGYRRKFHEKHHSHREFPFYGDYGSNYLYDN with phosphorylation of ‘S (Serine)’ and without any other modification. The theoretical size of H1 is 4928.17. Briefly, standard solid phase using Fmoc chemistry was used for the H1 synthesis. The peptide was purified using HPLC and characterized by electrospray ionization mass spectrometry. Lyophilized peptide powder was dissolved in phosphate buffered saline (PBS) to use for all the experiments. H1peptide was synthesized as Trifluoroacetic acid (TFA) salts with >95% purity and without any modification.

**Western Blot (WB), immuno-dot blot (IDB) and coomassie staining.** WB was performed following standard methods. Briefly, tear samples (2.5 μL) were electrophoresed on 12% NuPage bis-Tris gels (Invitrogen, Carlsbad, CA) and transferred to nitrocellulose membranes. Membranes were blocked with Tris-buffered saline containing 3% nonfat dry milk and 0.02% Tween 20 and incubated with 1:1000 rabbit anti-human Histatin-1 (H1) antibody (MBS2002621, Mybiosource, San Diego, CA) overnight at 4 °C and with 1:2000 goat anti-rabbit-HRP (BD Biosciences, San Jose, CA) as the secondary antibodies for 1 h. The membranes were developed using X-ray film and ECL Pro solution (PerkinElmer, Waltham, MA). For WB protein quantification was performed using BioDrop (Biochrom Ltd, Cambridge, UK). For IDB, 4 μL of serial dilutions of synthetic H1 (Syn.H1) were spotted in a nitrocellulose membrane and dried. Syn.H1 peptide and saliva were used as positive controls and a scrambled peptide and PBS were used as a negative control. Rabbit anti-human H1 antibody or Mouse anti-human H1 antibody (ab70024, Cambridge MA, Anti-Histatin 1) were used for primary antibodies. For detection, Goat anti-Rabbit (IRDy@ 680 RD) or Goat anti-mouse (IRDy@ 800 CW) were used as secondary antibodies. The relative intensity of each band was determined with the Li-Cor Odyssey application software.

**Multiple reaction monitoring (MRM).** MRM was performed for identification of presence of H1 in tears on the LC–MS/MS system (Agilent 1200 HPLC (Agilent Technologies, Santa Clara, CA) coupled with mass spectrometry (QTRAP 6500 Sciex, Framingham, MA)) for qualitative comparison of level of total protein between tear samples, we stained gels with Coomassie Brilliant Blue R-250 staining solution (Bio-rad Hercules, California, USA) as has been performed by published standards for qualitative comparison of protein levels in tears.
using a range of concentrations with (Syn-H1. Samples were centrifuged at 14,000 RPM for 9 minutes followed by injection of 10 μL of the supernatant into the LC-MS/MS system. The MRM was operated in the positive ion mode monitoring the 704.9–931.0 m/z, transitions for H1.

**Enzyme-linked immunosorbent assay (ELISA).** H1 concentration was determined by ELISA detection using a commercially available H1 ELISA kit (MBS2022124 H1, MyBioSource, Inc., San Diego, CA, USA) following the manufacturer’s instructions and read using a microplate reader (Biotek Synergy H1, Winooski, VT), and published protocols. Recent studies on salivary histatin and other proteins levels have been identify/quantify using ELISA kit (MyBioSource, Inc.).

**Statistical analysis.** The data were summarized by means and standard errors for continuous variables or by proportions for categorical variables. Demographic characteristics (age, sex) were compared between normal and ADDE groups using t-tests or Chi-square tests. The values of Schirmer I, OSDI and H1 concentration from two eyes were averaged first for each participant then were compared between groups using t-tests. The association between H1 concentration and other measures (age, sex, Schirmer I, OSDI and disease status) were assessed using mixed linear models, which could account for between eye correlation. Finally, logistic regression was used to estimate OR of disease from the averaged H1 levels from two eyes for each individual, followed by ROC analysis.

**References**

1. Stapleton, F. et al. TFOS DEWS II Epidemiology Report. *The Ocular Surface* 15, 334–365, https://doi.org/10.1016/j.jtos.2017.05.003 (2017).
2. Craig, J. P. et al. TFOS DEWS II Definition and Classification Report. *The Ocular Surface* 15, 276–283, https://doi.org/10.1016/j.jtos.2017.05.006 (2017).
3. Bron, A. J. et al. TFOS DEWS II pathophysiology report. *The Ocular Surface* 15, 438–510, https://doi.org/10.1016/j.jtos.2017.05.011 (2017).
4. De Smet, K. & Contreras, R. Human antimicrobial peptides: defensins, cathelicidins and histatins. *Biotechnol Lett* 27, 1337–1347, https://doi.org/10.1007/s10529-005-0936-5 (2005).
5. Hancock, R. E. W., Haney, E. E. & Gill, E. E. The immunology of host defense peptides: beyond antimicrobial activity. *Nature Reviews Immunology*, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved, https://doi.org/10.1038/nri.2016.29, https://www.nature.com/articles/nri.2016.29?supplementary-information=16, 321 (2016).
6. Khurshid, Z. et al. Histatin peptides: Pharmacological functions and their applications in dentistry. *Saudi Pharmaceutical Journal* 25, 25–31, https://doi.org/10.1016/j.ajps.2016.04.027 (2017).
7. Imamura, Y. & Wang, P.-L. Salivary histatin 3 inhibits heat shock cognate protein 70-mediated inflammatory cytokine production through toll-like receptors in human gingival fibroblasts. *Journal of Inflammation* 11, 4, https://doi.org/10.1186/1476-9255-11-4 (2014).
8. Vitorino, R. et al. The role of salivary peptides in dental caries. *Biomed Chromatogr* 19, 214–222, https://doi.org/10.1002/bmc.438 (2005).
9. Campese, M., Sun, X., Bosch, J. A., Oppenheim, F. G. & Helmerhorst, E. J. Concentration and fate of histatins and acidic proline-rich proteins in the oral environment. *Archives of Oral Biology* 54, 345–353, https://doi.org/10.1016/j.archoralbio.2008.11.019 (2009).
10. Melino, S., Santone, C., Di Nardo, P. & Sarkar, B. Histatins: salivary peptides with copper(II)- and zinc(II)-binding motifs: perspectives for biomedical applications. *Fbs j* 281, 657–672, https://doi.org/10.1111/febs.12612 (2014).
11. Jensen, J., Uhlig, T., Kvien, T. & Axell, T. Characteristics of rheumatoid arthritis patients with self-reported sicca symptoms: evaluation of medical, salivary and oral parameters. *Oral diseases* 3, 254–261 (1997).
12. Winiarczyk, M. et al. Tear film proteome in age-related macular degeneration. *Gracies Arch Clin Exp Ophthalmol* 256, 1127–1139, https://doi.org/10.1007/s00417-018-3984-y (2018).
13. Giannobile, W. V. et al. Saliva as a diagnostic tool for periodontal disease: current state and future directions. *Periodontol 2000* 50, 52–64, https://doi.org/10.1111/j.1600-0757.2008.00288.x (2009).
14. H. Huang, L. C., Jean, D., Proske, R. J., Reins, R. Y. & McDermott, A. M. Ocular Surface Expression and In Vitro Activity of Antimicrobial Peptides. *Current Eye Research* 32, 595–609, https://doi.org/10.1080/02713683.2007.1046653 (2007).
15. Pierce, P. S. M., J. N. S. W. Detection of Histatin 5 in Normal Human Schirmer Strip Samples by Mass Spectroscopy. *ARVO Annual Meeting Abstract, Investigative Ophthalmology & Visual Science* 43 (2002).
16. Steele, P. S. & Rychwalski, P. Identification of antimicrobial defense peptides in human tear film by Schirmer strip extraction, Clinical Chemistry, suppl. AACC Annual Meeting; Washington, Vol. 52, Iss. S6, A20–A21 (2006).
17. Shah, D. et al. Histatin-1 Expression in Human Lachrimal Epithelium. *Plos One* 11, e0148018, https://doi.org/10.1371/journal. pone.0148018 (2016).
18. Übels, J. L. et al. Gene expression in human accessory lacrimal glands of Wolfring. *Investigative ophthalmology & visual science* 53, 6738–6747, https://doi.org/10.1167/iovs.12-10750 (2012).
19. van Dijk, I. A. et al. Human salivary peptide histatin-1 stimulates epithelial and endothelial cell adhesion and barrier function. *The FASEB Journal* 31, 3922–3933 (2017).
20. Tilibrak, S. et al. Tear fluid extracellular DNA: diagnostic and therapeutic implications in dry eye disease. *Investigative ophthalmology & visual science* 54, 8051–8061, https://doi.org/10.1167/iovs.13-12844 (2013).
21. Schifman, R. M., Christianson, M. D., Jacobson, G., Hirsch, J. D. & Reis, B. L. Reliability and validity of the Ocular Surface Disease Index. *Arch Ophthalmol* 118, 615–621 (2000).
22. Ali, M. et al. Evaluation of Accessory Lacrimal Gland in Muller’s Muscle Conjunctival Resection Specimens for Precursor Cell Markers and Biological Markers of Dry Eye Disease. *Current Eye Research* 42, 491–497, https://doi.org/10.1080/02713683.2016.1214966 (2017).
23. Pult, H. & Riede-Pult, B. Comparison of subjective grading and objective assessment in meibography. *Contact Lens & anterior eye: the journal of the British Contact Lens Association* 36, 22–27, https://doi.org/10.1016/j.clase.2012.02.073 (2013).
24. Yeotkar, N. S. et al. Functional and Morphologic Changes of Meibomian Glands in an Asymptomatic Adult Population. *Investigative ophthalmology & visual science* 57, 3996–4007, https://doi.org/10.1167/iovs.15-18467 (2016).
25. Green-Church, K. B., Nichols, K. K., Kleinholz, N. M., Zhang, L. & Nichols, J. J. Investigation of the human tear film proteome using multiple proteomic approaches. *Molecular Vision* 14, 456–470 (2008).
26. Zhou, L. et al. In-depth analysis of the human tear proteome. *J Proteomics* 75, 3877–3883, https://doi.org/10.1016/j.jprot.2012.04.053 (2012).
27. Picotti, P. & Aebersold, R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. *Nat Methods* 9, 555–566, https://doi.org/10.1038/nmeth2015.10 (2012).
28. Karnati, R., Laurie, D. E. & Laurie, G. W. Lacrimation and the tear proteome as natural replacement therapy for dry eye. Exp Eye Res 117, 39–52, https://doi.org/10.1016/j.exer.2013.05.020 (2013).
29. Galor, A. et al. Dry eye symptoms align more closely to non-ocular conditions than to tear film parameters. Br J Ophthalmol 99, 1126–1129, https://doi.org/10.1136/bjo.2014-306481 (2015).
30. Shah, D., Ali, M., Shukla, D., Jain, S. & Aakul, V. Effects of histatin-1 peptide on human corneal epithelial cells. PLoS One 12, e0178030, https://doi.org/10.1371/journal.pone.0178030 (2017).
31. Torres, P., Castro, M., Reyes, M. & Torres, V. A. Histatinis, wound healing, and cell migration. Oral Dis. https://doi.org/10.1111/odi.12816 (2017).
32. Oyanian, M. et al. In Vivo Efficacy of Histatin-1 in a Rabbit Animal Model. Current Eye Research, 1–6, https://doi.org/10.1080/02713683.2018.1490772 (2018).
33. Narayanan, S., Miller, W. L. & McDermott, A. M. Expression of human β-defensins in conjunctival epithelium: relevance to dry eye disease. Investigative ophthalmology & visual science 44, 3795–3801 (2003).
34. Schnetler, R., Gillan, W. & Koorsen, G. Immunological and antimicrobial molecules in human tears: a review and preliminary report. African Vision and Eye Health 71, 123–132 (2012).
35. McNamara, N. A. et al. Reduced Levels of Tear Lacratin Are Associated With Corneal Neuropathy in Patients With the Ocular Component of Sjogren’s Syndrome. Investigative ophthalmology & visual science 57, 5237–5243, https://doi.org/10.1167/iovs.16-19390 (2016).
36. Badamchian, M. et al. Identification and quantification of thymosin β4 in human saliva and tears. Annals of the New York Academy of Sciences 1112, 458–465 (2007).
37. Soria, J. et al. Tear proteome and protein network analyses reveal a novel pentamer panel for tear film characterization in dry eye and meibomian gland dysfunction. Journal of Proteomics 78, 94–112, https://doi.org/10.1016/j.jprot.2012.11.017 (2013).
38. Massoudi, S., Zhong, L., Raftery, M. J., Stapleton, F. J. & Wilcox, M. D. Method development for quantification of five tear proteins using selected reaction monitoring (SRM) mass spectrometry. Investigative ophthalmology & visual science 55, 767–775 (2014).
39. Dammeyer, S. et al. Combined Targeted Analysis of Metabolites and Proteins in Tear Fluid With Regard to Clinical Applications. Translational vision science & technology 7, 22–22 (2018).
40. Jung, J. H. et al. Proteomic analysis of human lacrimal and tear fluid in dry eye disease. Scientific Reports 7, 13367 (2017).
41. Wong, T. C. T. et al. Proteomic profiling of inflammatory signaling molecules in the tears of patients on chronic glucocorticoid medication. Investigative ophthalmology & visual science 52, 7385–7391 (2011).
42. Glasson, M., Stapleton, F. & Wilcox, M. Lipid, lipase and lipocalin differences between tolerant and intolerant contact lens wearers. Current eye research 25, 223–235 (2002).
43. Caffery, B. et al. Tear lipocalin and lysozyme in Sjögren and non-Sjögren dry eye. Optometry and Vision Science 85, 661–667 (2008).
44. Grus, F. H., Sabuncuo, P. & Augustin, A. J. Analysis of tear protein patterns of dry-eye patients using fluorescent staining dyes and two-dimensional quantification algorithms. Electrophoresis 22, 1845–1850 (2001).
45. Cron, A. J. et al. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocular Surface 5, 108–152 (2007).
46. Lemp, M. A. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. The CLAO journal: official publication of the Contact Lens Association of Ophthalmologists. Inv 21, 221–232 (1995).
47. Cron, A. J. Diagnosis of Dry Eye. Survey of Ophthalmology 45, S221–S226, https://doi.org/10.1016/S0039-6257(00)00201-0 (2001).
48. Wolfssohn, J. S. et al. TFOS DEWS II Diagnostic Methodology report. The Ocular Surface 15, 539–574, https://doi.org/10.1016/j.os.2017.05.001 (2017).
49. Ogawa, Y. et al. International Chronic Ocular Graft-vs-Host Disease (GVHD) Consensus Group: Proposed Diagnostic Criteria for Chronic GVHD (Part I). Scientific Reports 3, 3419, https://doi.org/10.1038/srep03419 (2013).
50. Hamrah, P., Alipour, F., Jiang, S., Sohn, J. H. & Foulks, G. N. Optimizing evaluation of Lissamine Green parameters for ocular surface staining. Eye (London, England) 25, 1429–1434, https://doi.org/10.1038/eye.2011.184 (2011).
51. Agha-Hosseini, F., Mirzaii-Dizgah, I. & Mirjalili, N. Relationship of unstimulated saliva cortisol level with severity of oral dryness feeling in menopausal women. Aust Dent J 56, 171–174, https://doi.org/10.1111/1834-7819.2011.01320.x (2011).
52. Takahara, S., Yanagishita, M., Podyma-Inoue, K. A. & Kawaguchi, Y. Degradation of MUC7 and MUC5B in human saliva. PLoS One 8, e69059, https://doi.org/10.1371/journal.pone.0069059 (2013).
53. Sarkar, J. et al. Corneal neurotoxicity due to topical benzalkonium chloride. Investigative ophthalmology & visual science 53, 1792–1802, https://doi.org/10.1167/iovs.11-8775 (2012).
54. Seki, H. et al. The Anti-Inflammatory and Proresolving Mediator Resolvin E1 Protects Mice from Bacterial Pneumonia and Acute Lung Injury. The Journal of Immunology 184, 836, https://doi.org/10.4049/jimmunol.1001809 (2010).
55. Sonawane, S. et al. Ocular surface extracellular DNA and nuclease activity imbalance: a new paradigm for inflammation in dry eye disease. Investigative ophthalmology & visual science 53, 8253–8263, https://doi.org/10.1167/iovs.10-40340 (2012).
56. Colombo, N. H. et al. Antimicrobial peptides in saliva of children with severe early childhood caries. Archives of Oral Biology 69, 40–46, https://doi.org/10.1016/j.archoralbio.2016.05.009 (2016).

Acknowledgements

Portions of this work were carried out in the Protein Core via the Research Resources Center at the University of Illinois at Chicago. We thank Christine Mun for her expert help with sample collection. VKA: National Institutes of Health, National Eye Institute K08 EY024399, Department of Defense, Congressionally Directed Medical Research Program, Vision Research Program W81XWH-17-1-0122, Veterans Affairs Office of Research and Development I01BX004069, Unrestricted Grant from Research to Prevent Blindness, New York, NY, National Institutes of Health, National Eye Institute P30 EY001792, National Institutes of Health, National Eye Institute R01EY029409. SJ: National Institutes of Health, National Eye Institute R01 EY023656, National Institutes of Health, National Eye Institute R01 EY024966, Unrestricted Grant from Research to Prevent Blindness, New York, NY, National Institutes of Health, National Eye Institute P30 EY001792. DC: Unrestricted Grant from Research to Prevent Blindness, New York, NY, National Institutes of Health, National Eye Institute P30 EY001792.

Author Contributions

S.K.- Conceptualize, experiment design, data collection, analysis, interpretation and manuscript writing. K.N.S.- Experiment design, Data analysis, Conceptualize, interpretation, data collection, manuscript writing. D.C.- Data analysis and manuscript writing. B.S.L.- Data analysis and collection and manuscript writing. B.S.- Data collection and analysis and manuscript preparation. D.S.- Data interpretation and manuscript writing. M.A.- Data interpretation and manuscript writing. A.B.- Data interpretation and manuscript writing. S.J.- Data interpretation, manuscript writing. V.K.A.- Conceptualize, analysis, interpretation and manuscript writing.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-46623-9.

Competing Interests: Vinay Aakalu and Sandeep Jain are co-inventors on a patent application owned by the Board of Trustees of The University of Illinois related to some of the topics in this manuscript.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019